Aclaris Therapeutics (ACRS) showcased its clinical pipeline and balance-sheet strength at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on Thursday, Sept. 10, telling investors its cash position covers key milestone work through late 2028.
CEO Dr. Neal Walker said the company's current cash reserves will fund asthma and atopic dermatitis Phase 2B trials, proof-of-concept work in lichen planus and eosinophilic esophagitis, and both ITK inhibitor programs through proof-of-concept. That leaves only partial coverage for the Phase 2B atopic dermatitis study, he noted.
Aclaris currently trades at a market capitalization of roughly $810 million and carries a current ratio of 3.46, meaning liquid assets comfortably exceed short-term obligations. Shares have climbed 173% over the trailing year and 85% year-to-date.
The company is advancing three leading programs. ATI-052 is a bispecific antibody targeting TSLP and IL-4Rα for asthma and atopic dermatitis. ATI-2138 is an oral selective ITK/JAK3 inhibitor being tested in a basket study for oral lichen planus. A third program, ATI-9494, is an adjacent next-generation ITK inhibitor.
For lichen planus, Aclaris is running a Phase 1B basket study evaluating ATI-2138 across three disease phenotypes — mucosal, cutaneous and scalp disease. The trial is dosing approximately 40 patients per dose group at 10 mg and 20 mg twice daily plus placebo. The primary endpoint is the Oral Disease Severity Score at 16 weeks, with interim analysis planned once roughly 60% of the mucosal cohort reaches that mark. Top-line data is expected in the second half of 2027, and early regulatory discussions about a registrational study could begin in the first half of 2027 if interim results are positive. Walker described oral lichen planus as a more-than-$1-billion market, noting no therapies are currently approved and existing treatments such as corticosteroids, cyclosporine and Plaquenil carry failure rates around 60%.
In asthma, ATI-052 is set to enter a Phase 2B trial in the fourth quarter of 2024, following a single-dose Phase 1B study tracking biomarkers through day 43. In atopic dermatitis, the Phase 1B load-in design includes efficacy assessment from week 8 through week 20, with an enriched population skewed toward severe disease.
For the EoE indication, Aclaris highlighted that its ITK program demonstrated biochemical potency roughly 25 times that of rival Corvus Pharmaceuticals' program and cellular potency 10 times higher, along with a two-to-three-times longer half-life supporting once-daily dosing. Eosinophil-suppression data showed more than a 70% absolute reduction in healthy volunteers.
The presentations drew comparisons to competing programs from Sanofi, Pfizer, Bristol Myers Squibb and Amgen, all targeting the same type 2 inflammation pathway for asthma and atopic diseases.
